CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells

Leukemia

Volumn 27, Issue 5, 2013, Pages 1177-1181

  Vaisitti, T ^a,b   Serra, S ^b   Pepper, C ^c   Rossi, D ^d   Laurenti, L ^e   Gaidano, G ^d   Malavasi, F ^a   Deaglio, S ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Human Genetics Foundation   (Italy)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; GELATINASE B;

CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN CELL; LETTER; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; ZYMOGRAPHY;

ANTIGENS, CD38; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTEGRIN ALPHA4; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; UP-REGULATION;

EID: 84877605640     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.260     Document Type: Letter

References (15)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
3. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008; 26: 4497-4503.
4. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011; 118: 3470-3478.
5. Deaglio S, Aydin S, Grand MM, Vaisitti T, Bergui L, D'Arena G et al. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med 2010; 16: 87-91.
6. Deaglio S, Vaisitti T, Zucchetto A, Gattei V, Malavasi F. CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. Semin Cancer Biol 2010; 20: 416-423.
7. Vaisitti T, Aydin S, Rossi D, Cottino F, Bergui L, D'Arena G et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010; 24: 958-969.
8. Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D et al. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia 2012; 26: 1301-1312.
9. Jaksic O, Paro MM, Kardum Skelin I, Kusec R, Pejsa V, Jaksic B. CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood 2004; 103: 1968-1969.
10. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, Sison C et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007; 110: 3352-3359.
11. Calissano C, Damle RN, Hayes G, Murphy EJ, Hellerstein MK, Moreno C et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009; 114: 4832-4842.
12. Redondo-Munoz J, Escobar-Diaz E, Samaniego R, Terol MJ, Garcia-Marco JA, Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006; 108: 3143-3151.
13. Buggins AG, Levi A, Gohil S, Fishlock K, Patten PE, Calle Y et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011; 154: 216-222.
14. Caligaris-Cappio F, Bergui L, Tesio L, Corbascio G, Tousco F, Marchisio PC. Cytoskeleton organization is aberrantly rearranged in the cells of B chronic lymphocytic leukemia and hairy cell leukemia. Blood 1986; 67: 233-239.
15. Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F. CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med 2008; 14: 210-218.